(Q35770190)

10 August 2017

1 reference

title

Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology (English)

1 reference

10 August 2017

1 reference

1 reference

Quiroz JA

1

1 reference

10 August 2017

Singh J

2

1 reference

10 August 2017

Gould TD

3

1 reference

10 August 2017

Denicoff KD

4

1 reference

10 August 2017

Zarate CA

5

1 reference

10 August 2017

Manji HK

6

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

9

1 reference

10 August 2017

issue

8

1 reference

10 August 2017

page(s)

756-776

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.mp.4001521

10 August 2017

exact match

0 references

cites work

Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Genetic linkage and association studies in bipolar affective disorder: a time for optimism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Neuroimaging studies of mood disorder effects on the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

The cellular neurobiology of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Volumetric MRI studies of mood disorders: do they distinguish unipolar and bipolar disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Volumetric brain imaging findings in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Cell pathology in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Endophenotypes in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

A bivariate genetic analysis of cerebral white matter hyperintensities and cognitive performance in elderly male twins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Evidence of white matter tract disruption in MRI hyperintensities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Subcortical lesion severity and orbitofrontal cortex volume in geriatric depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Evidence of subtle gray-matter pathologic changes in healthy elderly individuals with nonspecific white-matter hyperintensities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Neuroimaging in bipolar disorder: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Antidepressants and neuroplasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Stress and hippocampal plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Stress, Glucocorticoids, and Damage to the Nervous System: The Current State of Confusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Regulation of hippocampal neurogenesis in adulthood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

More hippocampal neurons in adult mice living in an enriched environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Restoring production of hippocampal neurons in old age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Reduced cell proliferation in the dentate gyrus is not correlated with the development of learned helplessness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Increased neurogenesis and brain‐derived neurotrophic factor in neurokinin‐1 receptor gene knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Course of illness, hippocampal function, and hippocampal volume in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Untreated Depression and Hippocampal Volume Loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Early life stress and inherited variation in monkey hippocampal volumes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Smaller hippocampal volume predicts pathologic vulnerability to psychological trauma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Dendritic reorganization in pyramidal neurons in medial prefrontal cortex after chronic corticosterone administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Psychiatric disorders associated with Cushing's syndrome. Epidemiology, pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Differential diagnosis and pathophysiology of Cushing's syndrome and primary affective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

A prospective study of psychiatric and psychological aspects of Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Serum cortisol response to transsphenoidal surgery for Cushing disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

The psychiatric side effects of corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Steroid psychosis: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Relationship between alternate-day corticosteroid therapy and behavioral abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Mineralocorticoid receptor function in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Antiglucocorticoid treatment of depression: double-blind ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Limited efficacy of ketoconazole in treatment-refractory major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Rapid reversal of psychotic depression using mifepristone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Dehydroepiandrosterone treatment of midlife dysthymia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Antagonists of the corticotropin releasing factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

The effects of CRA 1000, a non-peptide antagonist of corticotropin-releasing factor receptor type 1, on adaptive behaviour in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: correlation with drug exposure and anxiolytic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Interacting mediators of allostasis and allostatic load: towards an understanding of resilience in aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Dehydroepiandrosterone (DHEA) treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

An open label trial of C-1073 (mifepristone) for psychotic major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Effect of Chronic Administration of Selective Glucocorticoid Receptor Antagonists on the Rat Hypothalamic–Pituitary–Adrenocortical Axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

A nonsteroidal glucocorticoid receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Glucocorticoid Receptor Antagonism by Cyproterone Acetate and RU486

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Distinct components of spatial learning revealed by prior training and NMDA receptor blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Phenylglycine derivatives as antagonists of metabotropic glutamate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Age dependence of seizure-induced oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Corticosterone acutely prolonged N-methyl-d-aspartate receptor-mediated Ca2+ elevation in cultured rat hippocampal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Chronic corticosterone treatment induces parallel changes in N-methyl-D-aspartate receptor subunit messenger RNA levels and antagonist binding sites in the hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Endogenous activation of group-II metabotropic glutamate receptors inhibits the hypothalamic-pituitary-adrenocortical axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Comparison of the effects of ketamine and memantine on prolactin and cortisol release in men. a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

A field potential analysis on the effects of lamotrigine, GP 47779, and felbamate in neocortical slices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Presynaptic inhibition of excitatory neurotransmission by lamotrigine in the rat amygdalar neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--II. Biochemical properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Riluzole, a glutamate release inhibitor, and motor behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

The pharmacology and mechanism of action of riluzole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Effects of riluzole on rat cortical neurones: an in vitro electrophysiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Effects of depolarizing stimuli on calcium homeostasis in cultured rat motoneurones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Riluzole blocks dopamine release evoked by N-methyl-D-aspartate, kainate, and veratridine in the rat striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

An open-label trial of riluzole in patients with treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Antidepressant-like actions of an AMPA receptor potentiator (LY392098).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Tricyclic antidepressants block N-methyl-D-aspartate receptors: similarities to the action of zinc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Functional antagonists at the NMDA receptor complex exhibit antidepressant actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Down-regulation of cortical beta-adrenoceptors by chronic treatment with functional NMDA antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Differential effects of agents acting at various sites of the NMDA receptor complex in a place preference conditioning model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Antidepressant effects of ketamine in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Amantadine in depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Amantadine-induced aggressiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

21 January 2018

Memantine for dementia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Potential antidepressive properties of amantadine, memantine and bifemelane

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Fluorine-18 radiolabelling, biodistribution studies and preliminary PET evaluation of a new memantine derivative for imaging the NMDA receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Protective effects of felbamate against hypoxia in the rat hippocampal slice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Felbamate monotherapy has stimulant-like effects in patients with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Behavioral effects of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Evaluation of case reports of aplastic anemia among patients treated with felbamate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Zn2+: an endogenous modulator of ligand- and voltage-gated ion channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Alterations in serum and brain trace element levels after antidepressant treatment: part I. Zinc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Antidepressant-like properties of zinc in rodent forced swim test

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Stimulatory effect of paeoniflorin on the release of noradrenaline from ileal synaptosomes of guinea-pig in-vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Inhibition of glycogen synthase kinase-3beta by bivalent zinc ions: insight into the insulin-mimetic action of zinc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Current perspectives on the development of non-biogenic amine-based antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

NMDA and quisqualate reduce a Ca-dependent K+ current by a protein kinase-mediated mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Metabotropic glutamate receptors (mGluRs) are involved in early phase of memory formation: possible role of modulation of glutamate release

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

The mechanism of presynaptic long-term depression mediated by group I metabotropic glutamate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Glutamate receptor function in learning and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Synaptic plasticity and mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Alterations of cAMP response element-binding activity in the aged rat brain in response to administration of rolipram, a cAMP-specific phosphodiesterase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Behavioral effects of rolipram and structurally related compounds in mice: behavioral sedation of cAMP phosphodiesterase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Interaction of metoprolol with lorazepam and bromazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

The next generation of PDE4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Update on the therapeutic potential of PDE4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Why do mature CNS neurons of mammals fail to re-establish connections following injury--functions of bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Bcl-2 promotes regeneration of severed axons in mammalian CNS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Enhanced axonal growth from fetal human bcl-2 transgenic mouse dopamine neurons transplanted to the adult rat striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Overexpression of Bcl-2 in a murine dopaminergic neuronal cell line leads to neurite outgrowth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Social stress exacerbates stroke outcome by suppressing Bcl-2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Preclinical models: status of basic research in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Methodological considerations for the development of new treatments for bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Molecular and cellular mechanisms underlying mood stabilization in bipolar disorder: implications for the development of improved therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents--preclinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Treatment of major depression with steroid suppressive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Ketoconazole administration in hypercortisolemic depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

The relationship between the effects of metyrapone treatment on depressed mood and urinary steroid profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Ketoconazole in bipolar patients with depressive symptoms: a case series and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Molecular evidence for mitochondrial dysfunction in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Mitochondrial dysfunction in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Ethanolamine and phosphoethanolamine inhibit mitochondrial function in vitro: implications for mitochondrial dysfunction hypothesis in depression and bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Targeting cellular energy production in neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

The course of bipolar disorder and the nature of agitated depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Neuroimaging Abnormalities in the Amygdala in Mood Disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Enhancement of hippocampal neurogenesis by lithium

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

The pharmacology of CP-154,526, a non-peptide antagonist of the CRH1 receptor: a review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

A question of reliability

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

The role of excitatory amino acids and NMDA receptors in traumatic brain injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Corticosteroid regulation of ion channel conductances and mRNA levels in individual hippocampal CA1 neurons.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Riluzole inhibits the persistent sodium current in mammalian CNS neurons

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

NMDA and AMPA/kainate receptors are involved in the anticonvulsant activity of riluzole in DBA/2 mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Regulation of adult neurogenesis by excitatory input and NMDA receptor activation in the dentate gyrus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Cyloserine as an antidepressant agent

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Controlled trial of amantadine hydrochloride in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Memantine inhibits [3H]MK-801 binding to human hippocampal NMDA receptors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Felbamate: clinical and molecular aspects of a unique antiepileptic drug

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Felbamate neuroprotection against CA1 traumatic neuronal injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Selective antagonism of the anticonvulsant effects of felbamate by glycine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Zinc in depressive disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Effect of berberine on proliferation, cell cycle and apoptosis in HeLa and L1210 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

AMPA receptors: molecular and functional diversity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Neuropharmacology of AMPA and kainate receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Metabotropic glutamate receptors: electrophysiological properties and role in plasticity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Heterologous expression of metabotropic glutamate receptors in adult rat sympathetic neurons: subtype-specific coupling to ion channels

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Group I and group III metabotropic glutamate receptor subtypes provide enhanced neuroprotection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Administration of a cAMP phosphodiesterase 4 inhibitor enhances antidepressant-induction of BDNF mRNA in rat hippocampus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Results of a phase II study of the antidepressant effect of rolipram

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Optic nerve crush: axonal responses in wild-type and bcl-2 transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Increase of bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Pramipexole for bipolar II depression: a placebo-controlled proof of concept study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

The role of the extracellular signal-regulated kinase signaling pathway in mood modulation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Treatment of major depression with metyrapone and hydrocortisone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Cortisol synthesis inhibition: A new treatment strategy for the clinical and endocrine manifestations of depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001521

7 January 2021

Identifiers

DOI

10.1038/SJ.MP.4001521

1 reference

10 August 2017

1 reference